Skip to main content

Quest Diagnostics company profile

  • DGX · NYSE
  • Healthcare
  • Health Care Services
  • S&P 500
$262.21+1.01%Close 16 Nov 2026 · Market value $28.35B

About Quest Diagnostics

Quest Diagnostics is a provider of diagnostic information services, offering clinical laboratory testing, anatomic pathology services, and insights derived from its laboratory results. Its main offerings include routine, non-routine and Advanced Diagnostics tests, along with Collaborative Lab Solutions for hospital laboratories, reference testing, and consumer-initiated testing through QuestHealth.com. Its customers include physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers. The company operates principally in the United States, with approximately 2,400 patient service centers, and also serves customers in other countries through its reference testing business.

A summary of the business section of the company's latest annual report, filed 26 Feb 2026.

Company facts

TickerDGX · NYSE
SectorHealthcare
IndustryHealth Care Services
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1022079
Latest annual report10-K, filed 26 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
James E. DavisCEO and President · Director489K · < 1%Sale under a 10b5-1 plan, 1 Sep 2026
Catherine T. DohertyExecutive Vice President135K · < 1%Grant or award, 3 Nov 2026
Michael E. PrevoznikSVP & General Counsel113K · < 1%Gift, 28 Aug 2026
Sam A. SamadExecutive Vice President &amp; CFO83.8K · < 1%Grant or award, 21 Oct 2026
Karthik KuppusamySVP, Clinical Solutions40.8K · < 1%Code L, 21 Oct 2026
Timothy L. MainDirector24.6K · < 1%Code L, 21 Oct 2026
Vicky B. GreggDirector15.4K · < 1%Grant or award, 21 Oct 2026
Denise M. MorrisonDirector6.6K · < 1%Grant or award, 20 May 2026
Luis A. Diaz, Jr.Director2.4K · < 1%Grant or award, 20 May 2026
Robert B. CarterDirector1.5K · < 1%Code L, 21 Oct 2026
Wright L. Lassiter IIIDirector1.5K · < 1%Code L, 21 Oct 2026
Deppe Michael JSVP, Corp. Controller &amp; CAO—Option exercise, 13 Nov 2026
Plewman PatrickSVP for Diagnostic Services—Option exercise, 9 Nov 2026
Ramachandran SubuSVP, Regional Businesses—Grant or award, 3 Nov 2026
DELANEY MARK ESVP &amp; Chief Commercial Officer—Grant or award, 3 Nov 2026
Gary M. PfeifferDirector—Sale under a 10b5-1 plan, 26 Oct 2026
Tracey C. DoiDirector—Grant or award, 20 May 2026
Timothy M. RingDirector—Grant or award, 20 May 2026
WENTWORTH TIMOTHY CDirector—Grant or award, 20 May 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

DGX in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.